Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 5: Line 5:
 
!Blood
 
!Blood
 
!CNS
 
!CNS
  +
!Vitreous
 
!Urine
 
!Urine
 
!Prostate
 
!Prostate
 
!Necrotic
 
!Necrotic
 
|-
 
|-
! colspan="7" |Antibiotics: β-Lactams
+
! colspan="8" |Antibiotics: β-Lactams
 
|-
 
|-
 
| rowspan="3" |[[Penicillins]]
 
| rowspan="3" |[[Penicillins]]
Line 15: Line 16:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 22: Line 24:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 29: Line 32:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +†
 
| style="text-align:center" | +†
Line 37: Line 41:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 44: Line 49:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 51: Line 57:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +†
 
| style="text-align:center" | +†
Line 58: Line 65:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 65: Line 73:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 73: Line 82:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 80: Line 90:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 88: Line 99:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
! colspan="7" |Antibiotics: Non-β-Lactams
+
! colspan="8" |Antibiotics: Non-β-Lactams
 
|-
 
|-
 
|[[Aminoglycosides]]
 
|[[Aminoglycosides]]
Line 98: Line 110:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 106: Line 119:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 114: Line 128:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–?
 
| style="text-align:center" |–?
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 122: Line 137:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 130: Line 146:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 138: Line 155:
 
| +
 
| +
 
|–
 
|–
  +
|
 
| +
 
| +
 
|
 
|
Line 146: Line 164:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 154: Line 173:
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" |–
 
| style="text-align:center" |–
Line 162: Line 182:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 170: Line 191:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 178: Line 200:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 186: Line 209:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |–
 
| style="text-align:center" |–
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
Line 193: Line 217:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
|-
 
|-
! colspan="7" |Antifungals
+
! colspan="8" |Antivirals
  +
|-
  +
|
  +
|[[acyclovir]] / [[valacyclovir]]
  +
|
  +
|
  +
| +
  +
|
  +
|
  +
|
  +
|-
  +
|
  +
|[[ganciclovir]]
  +
|
  +
|
  +
| +
  +
|
  +
|
  +
|
  +
|-
  +
|
  +
|[[foscarnet]]
  +
|
  +
|
  +
|
  +
|
  +
|
  +
|
  +
|-
  +
! colspan="8" |Antifungals
 
|-
 
|-
 
|[[Azoles]]
 
|[[Azoles]]
Line 203: Line 257:
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 211: Line 266:
 
| style="text-align:center" | +
 
| style="text-align:center" | +
 
| style="text-align:center" |
 
| style="text-align:center" |
  +
|
 
| style="text-align:center" |–
 
| style="text-align:center" |–
 
| style="text-align:center" |
 
| style="text-align:center" |
Line 219: Line 275:
 
!Blood
 
!Blood
 
!CNS
 
!CNS
  +
!
 
!Urine
 
!Urine
 
!Prostate
 
!Prostate

Revision as of 13:11, 13 February 2021

Summary

Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
Antibiotics: β-Lactams
Penicillins β-lactamase inhibitors
ampicillin +
piperacillin-tazobactam +†
Cephalosporins first-generation cephalosporins
second-generation cephalosporins
third-generation cephalosporins +†
cefepime +
ceftazidime + +
Cephamycins cephamycins
cefoxitin
Carbapenems imipenem +
Antibiotics: Non-β-Lactams
Aminoglycosides
Chloramphenicol chloramphenicol +
Fluoroquinolones –? + +
Fosfomycin fosfomycin +
Lincosamides clindamycin +
Lipopeptides daptomycin + +
Macrolides macrolides +
Nitrofurans nitrofurantoin +
Nitroimidazoles metronidazole +
Rifamycins rifampin +
Sulfonamides trimethoprim-sulfamethoxazole +
Tetracyclines tetracyclines +
doxycycline + +
Antivirals
acyclovir / valacyclovir +
ganciclovir +
foscarnet
Antifungals
Azoles fluconazole +
Echinocandins +
Class Antimicrobial Blood CNS Urine Prostate Necrotic
  • † if inflammation present

Prostate

  • Poorly penetrated by most antibiotics
  • Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
  • Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
  • TMP-SMX often used, though conflicting data about its penetration into the prostate
  • Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
  • Third-generation cephalosporins and carbapenems can be used
  • Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful

Bone

  • Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral β-lactams which nevertheless have no worse outcomes1

References

  1. ^  Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.